Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK112 alone or with chemotherapy as neoadjuvant/adjuvant therapy for resectable non-small cell lung cancer
CTR20220028Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Mar 2022; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220028.